GIFLF - Grifols, S.A.
| Previous Close | 11.65 |
| Open | 11.65 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 11.65 - 11.65 |
| 52 Week Range | 7.90 - 21.00 |
| Volume | |
| Avg. Volume | 153 |
| Market Cap | 7.501B |
| Beta (5Y Monthly) | 0.43 |
| PE Ratio (TTM) | 35.30 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jun 03, 2021 |
| 1y Target Est | N/A |
- GlobeNewswire
Grifols Launches AlphaID™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic COPD
Now available in the U.S., this free, innovative genetic health risk service lets consumers screen for their risk of alpha1-antitrypsin deficiency (alpha-1) through a small saliva sample they can collect right at home without needing to visit a healthcare professionalAlpha-1 is the most common genetic risk factor for chronic obstructive pulmonary disease (COPD), a group of respiratory diseases affecting around 16 million Americans and the fourth-leading cause of death in the U.S.1As the leader i
- GlobeNewswire
GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and Pathogens
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today it has entered into a contract with the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to demonstrate the utility of its first-in-class recombi
- CNW Group
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada
Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global leader in plasma medicines with more than 110 years contributing to improve the health and well-being of people, today announced it has signed a pioneering long-term agreement with Canadian Blood Services, Canada's national blood authority, to greatly increase the country's self-sufficiency in immunoglobulin (Ig) medicines, essential plasma-protein therapies used to treat a wide range of immunodeficiencies and other medical conditions.
